EyePoint Financials
EyePoint (EYPT) reported $31.4M in revenue for fiscal year 2025, down 27.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
EyePoint’s business is currently an equity-funded R&D program, while its small revenue base contributes little to covering costs.
Between FY2023 and FY2025, operating cash flow moved from$1.9M to-$240.1M , showing how sharply the business shifted from near self-funding to heavy cash consumption. Cash still ended FY2025 at$101.8M because financing inflow reached$173.6M , so reported liquidity was preserved externally rather than earned through operations.
The widening loss is mostly a research intensity story, not primarily a top-line one: FY2025 R&D reached
Share count rose from 49.0M to 82.8M between FY2023 and FY2025, showing equity issuance has been a central funding source. With no long-term debt reported in the last three years, that choice lowers fixed repayment obligations, but it also places more of the funding burden on shareholders instead of lenders.
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of EyePoint's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for EyePoint, and counted as zero in the overall score.
EyePoint scores -0.66, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($458.6M) relative to total liabilities ($57.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
EyePoint passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
EyePoint reported a net loss of $232.0M while operations used $240.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
EyePoint reported an operating loss of $243.4M against $33K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
EyePoint generated $31.4M in revenue in fiscal year 2025. This represents a decrease of 27.5% from the prior year.
EyePoint's EBITDA was -$241.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 67.1% from the prior year.
EyePoint reported -$232.0M in net income in fiscal year 2025. This represents a decrease of 77.2% from the prior year.
EyePoint earned -$3.17 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 36.6% from the prior year.
Cash & Balance Sheet
EyePoint recorded an outflow of $243.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 86.8% from the prior year.
EyePoint held $101.8M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
EyePoint's ROE was -75.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 36.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
EyePoint invested $221.0M in research and development in fiscal year 2025. This represents an increase of 66.3% from the prior year.
EyePoint invested $3.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 19.1% from the prior year.
Not reported for fiscal year 2025.
EYPT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $31.4M-27.5% | $43.3M-6.0% | $46.0M+11.1% | $41.4M+12.1% | $36.9M+7.3% | $34.4M+69.1% | $20.4M+345.5% | $4.6M-39.4% | $7.5M+365.4% | $1.6M-93.9% | $26.6M+664.9% | $3.5M+62.1% | $2.1M-39.2% | $3.5M-29.0% | $5.0M |
| R&D Expenses | $262.7M | $221.0M+66.3% | $132.9M+105.6% | $64.7M+30.3% | $49.6M+74.2% | $28.5M+63.6% | $17.4M+13.4% | $15.4M-16.9% | $18.5M+24.3% | $14.9M+3.5% | $14.4M+19.0% | $12.1M+26.3% | $9.6M+36.7% | $7.0M-0.5% | $7.0M+2.5% | $6.9M |
| SG&A Expenses | $55.4M | $51.6M-1.4% | $52.4M+30.6% | $40.1M+15.2% | $34.8M+36.1% | $25.6M+23.4% | $20.7M+15.5% | $17.9M+16.3% | $15.4M+37.3% | $11.2M+24.7% | $9.0M+11.9% | $8.1M+7.9% | $7.5M+4.2% | $7.2M+4.4% | $6.9M-15.3% | $8.1M |
| Operating Income | -$317.0M | -$243.4M-66.9% | -$145.9M-94.3% | -$75.1M+24.7% | -$99.6M-80.3% | -$55.3M-48.2% | -$37.3M+22.1% | -$47.9M-22.7% | -$39.0M-110.1% | -$18.6M+14.7% | -$21.8M-439.1% | $6.4M+147.6% | -$13.5M-12.1% | -$12.0M+52.3% | -$25.2M-152.0% | -$10.0M |
| Interest Expense | N/A | $33K+135.7% | $14K-98.9% | $1.2M-60.9% | $3.2M-42.0% | $5.5M-24.2% | $7.3M+17.5% | $6.2M+161.5% | $2.4M | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $136K | $279K+210.0% | $90K+8.4% | $83K | $0 | $0 | $0 | $0 | $0 | $0+100.0% | -$155K-261.5% | $96K+173.8% | -$130K-11.1% | -$117K+30.8% | -$169K+22.5% | -$218K |
| Net Income | -$306.6M | -$232.0M-77.2% | -$130.9M-84.9% | -$70.8M+30.8% | -$102.3M-75.0% | -$58.4M-28.7% | -$45.4M+20.1% | -$56.8M+34.1% | -$86.1M-365.9% | -$18.5M+14.2% | -$21.5M-439.5% | $6.3M+147.5% | -$13.4M-12.2% | -$11.9M+52.1% | -$24.8M-187.8% | -$8.6M |
| EPS (Diluted) | — | -$3.17-36.6% | -$2.32-27.5% | -$1.82+33.6% | -$2.74-35.0% | -$2.03 | N/A | N/A | N/A | -$0.52+23.5% | -$0.68-423.8% | $0.21+142.9% | -$0.49+5.8% | -$0.52+56.3% | -$1.19-170.5% | -$0.44 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
EYPT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $364.0M-13.0% | $418.5M+17.8% | $355.2M+96.9% | $180.4M-31.5% | $263.4M+187.2% | $91.7M+25.7% | $73.0M-6.6% | $78.2M+318.5% | $18.7M-40.9% | $31.6M-2.3% | $32.4M+42.8% | $22.7M+39.5% | $16.2M-21.1% | $20.6M-56.3% | $47.1M |
| Current Assets | $328.7M-14.3% | $383.3M+11.2% | $344.8M+99.5% | $172.8M-27.3% | $237.7M+276.7% | $63.1M+51.3% | $41.7M-12.4% | $47.6M+168.3% | $17.7M-40.8% | $30.0M+0.4% | $29.8M+54.3% | $19.3M+55.2% | $12.5M-21.9% | $16.0M-37.1% | $25.4M |
| Cash & Equivalents | $101.8M+2.1% | $99.7M-64.6% | $281.3M+194.1% | $95.6M-46.5% | $178.6M+297.7% | $44.9M+102.2% | $22.2M-50.9% | $45.3M+167.8% | $16.9M+10.4% | $15.3M-19.9% | $19.1M+24.7% | $15.3M+122.3% | $6.9M+49.2% | $4.6M-64.2% | $12.9M |
| Inventory | $1.8M-21.3% | $2.3M-41.0% | $3.9M+35.3% | $2.9M-20.2% | $3.6M-32.2% | $5.3M+149.6% | $2.1M+666.3% | $279K | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $57.9M-29.4% | $82.0M-7.8% | $88.9M+5.8% | $84.0M+6.3% | $79.0M+7.9% | $73.2M+13.2% | $64.6M+59.5% | $40.5M+658.9% | $5.3M-50.3% | $10.7M+19.3% | $9.0M+16.2% | $7.7M-9.4% | $8.5M+22.8% | $7.0M-28.1% | $9.7M |
| Current Liabilities | $37.0M-24.5% | $49.0M-22.5% | $63.3M+83.2% | $34.5M+46.0% | $23.7M+58.9% | $14.9M+29.2% | $11.5M-46.3% | $21.5M+305.7% | $5.3M+3.9% | $5.1M+52.1% | $3.3M+57.5% | $2.1M-35.6% | $3.3M+3.9% | $3.2M-36.8% | $5.0M |
| Long-Term Debt | N/A | N/A | N/A | $29.3M-19.8% | $36.6M-3.7% | $38.0M-19.6% | $47.2M+168.0% | $17.6M | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $306.1M-9.0% | $336.5M+26.4% | $266.3M+176.4% | $96.4M-47.7% | $184.4M+894.4% | $18.5M+122.6% | $8.3M-77.9% | $37.6M+182.2% | $13.3M-36.1% | $20.9M-10.6% | $23.4M+56.6% | $14.9M+93.8% | $7.7M-43.5% | $13.6M-63.6% | $37.4M |
| Retained Earnings | -$1.1B-26.6% | -$873.0M-17.6% | -$742.1M-10.5% | -$671.4M-18.0% | -$569.1M-11.4% | -$510.7M-9.8% | -$465.3M-13.9% | -$408.5M-31.4% | -$310.8M-6.4% | -$292.2M-8.0% | -$270.7M+2.3% | -$277.0M-5.1% | -$263.7M-4.7% | -$251.8M-10.9% | -$226.9M |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
EYPT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$267.3M | -$240.1M-90.2% | -$126.2M-6832.1% | $1.9M+102.9% | -$65.0M-29.8% | -$50.1M-247.1% | -$14.4M+74.5% | -$56.7M-158.8% | -$21.9M-6.9% | -$20.5M-25.6% | -$16.3M-258.5% | $10.3M+196.5% | -$10.7M-22.0% | -$8.7M+2.8% | -$9.0M-183.9% | -$3.2M |
| Capital Expenditures | $4.0M | $3.3M-19.1% | $4.1M+16.3% | $3.5M+62.0% | $2.1M+1278.2% | $156K-56.9% | $362K+70.0% | $213K+97.2% | $108K-26.5% | $147K+30.1% | $113K-29.8% | $161K-35.1% | $248K+264.7% | $68K-83.2% | $405K+204.5% | $133K |
| Free Cash Flow | -$271.3M | -$243.4M-86.8% | -$130.3M-8001.9% | -$1.6M+97.6% | -$67.2M-33.6% | -$50.3M-239.6% | -$14.8M+74.0% | -$56.9M-158.5% | -$22.0M-6.7% | -$20.6M-25.6% | -$16.4M-262.1% | $10.1M+192.8% | -$10.9M-23.9% | -$8.8M+6.3% | -$9.4M-184.8% | -$3.3M |
| Investing Cash Flow | $114.9M | $68.6M+131.3% | -$219.4M-6517.0% | -$3.3M+80.8% | -$17.3M+47.9% | -$33.1M-9049.4% | -$362K-70.0% | -$213K+98.7% | -$16.9M-224.4% | $13.6M+404.3% | -$4.5M | N/A | N/A | $6.4M+949.2% | $606K+106.4% | -$9.5M |
| Financing Cash Flow | $191.7M | $173.6M+5.9% | $164.0M-12.3% | $187.1M+27211.6% | -$690K-100.3% | $216.9M+478.5% | $37.5M+10.7% | $33.9M-44.2% | $60.7M+613.5% | $8.5M-50.0% | $17.0M | N/A | N/A | $4.7M+3995.6% | $114K-98.9% | $10.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
EYPT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% | -108.3% | -235.0% | -853.6% | -246.4% | -1344.1% | 24.2% | -388.4% | -561.4% | -715.0% | -201.5% |
| Net Margin | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | -131.8% | -278.9% | -1884.2% | -245.2% | -1330.1% | 23.9% | -384.5% | -555.3% | -704.3% | -173.8% |
| Return on Equity | -75.8%-36.9pp | -38.9%-12.3pp | -26.6%+79.5pp | -106.1%-74.4pp | -31.7%+213.2pp | -244.8%+437.0pp | -681.8%-452.9pp | -228.8%-90.2pp | -138.6%-35.4pp | -103.2%-130.4pp | 27.2%+116.7pp | -89.5%+65.1pp | -154.6%+27.6pp | -182.1%-159.1pp | -23.1% |
| Return on Assets | -63.7%-32.5pp | -31.3%-11.3pp | -19.9%+36.8pp | -56.7%-34.5pp | -22.2%+27.3pp | -49.5%+28.3pp | -77.8%+32.3pp | -110.2%-11.2pp | -99.0%-30.8pp | -68.2%-87.8pp | 19.6%+78.5pp | -58.9%+14.3pp | -73.2%+47.3pp | -120.6%-102.3pp | -18.3% |
| Current Ratio | 8.88+1.1x | 7.81+2.4x | 5.45+0.4x | 5.00-5.0x | 10.05+5.8x | 4.24+0.6x | 3.62+1.4x | 2.22-1.1x | 3.35-2.5x | 5.88-3.0x | 8.91-0.2x | 9.10+5.3x | 3.77-1.2x | 5.020.0x | 5.04 |
| Debt-to-Equity | 0.19-0.1x | 0.24-0.1x | 0.330.0x | 0.30+0.1x | 0.20-1.8x | 2.05-3.6x | 5.67+5.2x | 0.47+0.5x | 0.00-0.5x | 0.51+0.1x | 0.39-0.1x | 0.52-0.6x | 1.11+0.6x | 0.51+0.3x | 0.26 |
| FCF Margin | -775.8% | -301.1% | -3.5% | -162.2% | -136.0% | -43.0% | -279.5% | -481.6% | -273.7% | -1014.1% | 38.2% | -314.4% | -411.3% | -266.8% | -66.5% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where EyePoint Ranks
Frequently Asked Questions
What is EyePoint's annual revenue?
EyePoint (EYPT) reported $31.4M in total revenue for fiscal year 2025. This represents a -27.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is EyePoint's revenue growing?
EyePoint (EYPT) revenue declined by 27.5% year-over-year, from $43.3M to $31.4M in fiscal year 2025.
Is EyePoint profitable?
No, EyePoint (EYPT) reported a net income of -$232.0M in fiscal year 2025.
What is EyePoint's EBITDA?
EyePoint (EYPT) had EBITDA of -$241.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is EyePoint's return on equity (ROE)?
EyePoint (EYPT) has a return on equity of -75.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is EyePoint's free cash flow?
EyePoint (EYPT) recorded an outflow of $243.4M in free cash flow during fiscal year 2025. This represents a -86.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is EyePoint's operating cash flow?
EyePoint (EYPT) recorded an outflow of $240.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are EyePoint's total assets?
EyePoint (EYPT) had $364.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are EyePoint's capital expenditures?
EyePoint (EYPT) invested $3.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does EyePoint spend on research and development?
EyePoint (EYPT) invested $221.0M in research and development during fiscal year 2025.
What is EyePoint's current ratio?
EyePoint (EYPT) had a current ratio of 8.88 as of fiscal year 2025, which is generally considered healthy.
What is EyePoint's debt-to-equity ratio?
EyePoint (EYPT) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is EyePoint's return on assets (ROA)?
EyePoint (EYPT) had a return on assets of -63.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is EyePoint's cash runway?
Based on fiscal year 2025 data, EyePoint (EYPT) had $101.8M in cash against an annual operating cash burn of $240.1M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is EyePoint's Altman Z-Score?
EyePoint (EYPT) has an Altman Z-Score of -0.66, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is EyePoint's Piotroski F-Score?
EyePoint (EYPT) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are EyePoint's earnings high quality?
EyePoint (EYPT) reported a net loss of $232.0M while operations used $240.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can EyePoint cover its interest payments?
EyePoint (EYPT) reported an operating loss of $243.4M against $33K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is EyePoint?
EyePoint (EYPT) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.